Compare Hasbro, Inc. (HAS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Mesoblast Limited — how do they compare? Hasbro, Inc. trades at $93.96 (market cap $13.05B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Hasbro, Inc. is far larger — about 7.5× Mesoblast Limited's market cap, and Hasbro, Inc. pays a 3.03% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Mesoblast Limited for 15 Days on average.
| HAS | MESO | |
|---|---|---|
Market Cap | $13.05B | $1.75B |
Volume | 1,207,655 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $20.96 |
52-Week Low | $70.95 | $13.19 |
Typical Hold Time | 97 Days | 15 Days |
Enterprise Value | $15.24B | $1.83B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $94.22, up 3.82% today, showing strong momentum after recent earnings beats. The stock maintains a bullish technical stance with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 64.41% gross margins and impressive ROE of 167.83%, despite a net loss in 2025. Analyst consensus remains positive with 51.52% buy ratings and a $107.60 price target, representing 14% upside potential from current levels.
Investment outlook appears favorable with strong gaming segment growth and cost-saving initiatives driving projected 2026 net income of $794 million. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The upcoming Q3 2026 earnings report on October 20 will be crucial for validating the company's turnaround trajectory and growth projections.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
